Amyloid pathology influences Aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies

Journal of Alzheimer's Disease

Volumn 35, Issue 1, 2013, Pages 137-146

  Slaets, Sylvie ^a,c,d   Theuns, Jessie ^a,b   Sleegers, Kristel ^a,b   Verstraeten, Aline ^a,b   De Leenheir, Evelyn ^a   Luyckx, Jill ^a   Martin, Jean Jacques ^a   Van Broeckhoven, Christine ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c ZNA Hospital Network Antwerp   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; autopsy confirmed; biological markers; dementia; dementia with Lewy bodies

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; GLUCOSYLCERAMIDASE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY;

EID: 84876355554     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122176     Document Type: Article

References (41)

1. Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, Katsuse O, Uchikado H, Aoki N, Kosaka K, Arai H, SatoK(2010) Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 486, 19-23.
2. Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115, 427-436.
3. McKeith IG, DicksonDW,Lowe J,EmreM, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, YamadaM(2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
4. Ballard C, Ziabreva I, Perry R, Larsen JP, O'brien J, McKeith I, Perry E, Aarsland D (2006) Differences in neuropathologic characteristics across the Lewybody dementia spectrum. Neurology 67, 1931-1934. (Pubitemid 44967366)
5. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60, 1586-1590. (Pubitemid 36618082)
6. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
7. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M,DeDeyn PP, Bancher C, Cras P,Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555-1562. (Pubitemid 29220627)
8. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S (2010) Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 31, 1867-1876.
9. Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107, 165-173.
10. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H,Van Everbroeck B, Cras P, Martin JJ,Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159. (Pubitemid 351822410)
11. Vanderstichele H, Bibl M, Engelborghs S, Le BN, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73.
12. Rijk PD, Del-Favero J (2007) novoSNP3: Variant detection and sequence annotation in resequencing projects. Methods Mol Biol 396, 331-344. (Pubitemid 350190050)
13. KoprivicaV, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ,Tayebi N, SidranskyE(2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66, 1777-1786. (Pubitemid 30480085)
14. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP (2007) No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320-2326. (Pubitemid 47327622)
15. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
16. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404. (Pubitemid 44469160)
17. Jellinger KA (1998) The neuropathological diagnosis of Alzheimer disease. J Neural Transm Suppl 53, 97-118. (Pubitemid 28361772)
18. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379. (Pubitemid 32217453)
19. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, KlafkiHW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-betapeptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187.
20. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64, 850-855.
21. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34, 107-112.
22. Brunnstrom H, Hansson O, Zetterberg H, Londos E, Englund E (2012) Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. Int J Geriatr Psychiatry 33, 807-822.
23. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, SmallGW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
24. Singleton AB, Wharton A, O'Brien KK,WalkerMP,McKeith IG, Ballard CG, O'brien J, Perry RH, Ince PG, Edwardson JA, Morris CM (2002) Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord 14, 167-175. (Pubitemid 36151483)
25. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67, 308-316.
26. Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H (2000) Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 21, 735-740.
27. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon4 allele. Biol Psychiatry 56, 670-676. (Pubitemid 39446849)
28. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656. (Pubitemid 36246085)
29. Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H (2007) No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130, e82.
30. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041. (Pubitemid 44684523)
31. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81, 608-610.
32. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102. (Pubitemid 38044645)
33. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Burger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Blaser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E (2006) Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44, 1472-1480. (Pubitemid 44967698)
34. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S (2009) Improved discrimination of autopsyconfirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P. Neurochem Int 55, 214-218.
35. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC,McKeelDWJr, FarlowM,Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ (2003) Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsyconfirmed dementia diagnoses? Arch Neurol 60, 1696-1702. (Pubitemid 37521622)
36. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, Del ST (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60, 1218-1222. (Pubitemid 37099626)
37. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz- Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19, 164-170. (Pubitemid 40868045)
38. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 19, 109-116.
39. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA (2007) In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 69, 356-359. (Pubitemid 47205662)
40. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257, 359-366.
41. Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) longitudinal stability of cerebrospinal fluid biomarker levels: Fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. J Alzheimers Dis 33, 807-822.